SCHEDULE: BlackRock Discloses 6.9% Stake in C4 Therapeutics
Schedule 13G Filing
BlackRock, Inc. has reported a beneficial ownership of 6.9% of C4 Therapeutics, Inc.'s common stock as of June 30, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of C4 Therapeutics, Inc. common stock.
- As of June 30, 2026, BlackRock beneficially owns 7,678,906 shares, representing 6.9% of the class of securities.
- This ownership includes sole voting power over 7,586,715 shares and sole dispositive power over 7,678,906 shares.
- The filing clarifies that this reflects securities owned by certain reporting business units of BlackRock, Inc. and its subsidiaries.
- No single person's interest in C4 Therapeutics, Inc. exceeds five percent of the total outstanding common shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates.
Positives
- BlackRock, a significant institutional investor, holds a substantial stake in C4 Therapeutics, Inc., suggesting confidence in the company's potential.
- The filing indicates that BlackRock's ownership is not for the purpose of changing or influencing control of the issuer.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future performance.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that significant holdings by major asset managers like BlackRock in biotechnology companies, particularly those in clinical development stages like C4 Therapeutics, often signal investor conviction in the company's pipeline and long-term prospects.
Stakeholder Impact
- Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively as a sign of confidence, but it does not directly impact current share value or dividends.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney dated for BlackRock, Inc. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 06/30/2026 | Date of event requiring filing of Schedule 13G. |
| 07/27/2026 | Date of certification and signature for the Schedule 13G filing. |
Keywords
C4 Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.